focus -WSS

focus

author：comprehensive 2025-09-27 23:53:35 - browse：4

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

WSS

Stem cell clinics for heart failure: buyer be wary

Medicare coverage of Wegovy, once blocked, now looks possible

Readout Newsletter: Bristol, Sangamo, Gilead, and more

OTC birth control: A brief history of over the counter pill design

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

hotspot

focus

Wikipedia

Affirmative action in medical school literally saved lives

TytoCare raises $49 million to build out AI

Malaria cases in Florida and Texas: Here’s what you need to know

Change Healthcare outage fallout shows need for new oversight

After affirmative action ruling, medical educators look to 'holistic review'

A cyberattack has disrupted hospitals and health care in several states

Medical records are filled with copy

Amid AI frenzy, a top HHS official's quest to create safeguards

Anesthesiologist group: stop taking Ozempic before surgery

Pushing for an NIH office for post

Wikipedia

Medicare coverage of Wegovy, once blocked, now looks possible

As AI in medicine takes off, can 'human in the loop' prevent harm?

OTC birth control: A brief history of over the counter pill design

First U.S. drug developed to treat liver disease MASH is approved

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

OTC birth control: A brief history of over the counter pill design

knowledge

hotspot

entertainment

knowledge